HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Eric Van Cutsem Selected Research

Erlotinib Hydrochloride (CP 358,774)

7/2012VEGF pathway genetic variants as biomarkers of treatment outcome with bevacizumab: an analysis of data from the AViTA and AVOREN randomised trials.
5/2009Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer.
5/2006Chemotherapy-induced epidermal growth factor receptor activation determines response to combined gefitinib/chemotherapy treatment in non-small cell lung cancer cells.
8/2005The management of skin reactions in cancer patients receiving epidermal growth factor receptor targeted therapies.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Eric Van Cutsem Research Topics

Disease

120Neoplasms (Cancer)
12/2022 - 07/2004
117Colorectal Neoplasms (Colorectal Cancer)
10/2022 - 04/2002
42Disease Progression
12/2022 - 01/2004
41Adenocarcinoma
12/2022 - 08/2005
38Stomach Neoplasms (Stomach Cancer)
01/2022 - 01/2002
29Colonic Neoplasms (Colon Cancer)
11/2022 - 04/2002
29Neoplasm Metastasis (Metastasis)
01/2022 - 01/2007
20Pancreatic Neoplasms (Pancreatic Cancer)
12/2022 - 03/2004
20Neutropenia
10/2021 - 01/2004
19Fatigue
01/2021 - 10/2008
16Neuroendocrine Tumors (Neuroendocrine Tumor)
01/2022 - 01/2010
15Rectal Neoplasms (Rectal Cancer)
01/2021 - 02/2005
14Diarrhea
07/2022 - 01/2007
12Hypertension (High Blood Pressure)
01/2019 - 09/2009
10Microsatellite Instability
10/2022 - 09/2009
9Stomatitis
01/2018 - 01/2004
8Exanthema (Rash)
03/2015 - 10/2007
7Thrombocytopenia (Thrombopenia)
10/2021 - 10/2008
7Vomiting
01/2019 - 01/2007
7Nausea
01/2017 - 01/2004
6Anemia
01/2020 - 10/2008
6Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
04/2019 - 01/2005
5Carcinoma (Carcinomatosis)
10/2018 - 12/2004
5Febrile Neutropenia
01/2017 - 01/2013
5Carcinoid Tumor (Carcinoid)
12/2015 - 01/2004
3Adenomatous Polyposis Coli (Familial Adenomatous Polyposis)
04/2022 - 09/2011
3Inflammation (Inflammations)
08/2021 - 01/2018
3Cholangiocarcinoma
10/2020 - 01/2018
3Hepatocellular Carcinoma (Hepatoma)
01/2020 - 08/2010
3Infections
01/2018 - 02/2011
3Anorexia
01/2017 - 10/2008
3Cachexia
01/2016 - 01/2005

Drug/Important Bio-Agent (IBA)

51Fluorouracil (Carac)FDA LinkGeneric
08/2021 - 04/2002
34ErbB Receptors (EGF Receptor)IBA
08/2021 - 07/2004
33Irinotecan (Camptosar)FDA LinkGeneric
10/2022 - 04/2002
33Cetuximab (Erbitux)FDA Link
01/2021 - 07/2004
32Oxaliplatin (Eloxatin)FDA LinkGeneric
10/2022 - 04/2002
32Leucovorin (Folinic Acid)FDA Link
01/2021 - 04/2002
28Biomarkers (Surrogate Marker)IBA
01/2022 - 01/2004
28Bevacizumab (Avastin)FDA Link
12/2020 - 12/2004
20GemcitabineFDA Link
10/2021 - 03/2004
20Capecitabine (Xeloda)FDA Link
08/2021 - 04/2002
18Pharmaceutical PreparationsIBA
04/2022 - 01/2002
18Monoclonal AntibodiesIBA
01/2019 - 08/2005
17Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
10/2021 - 01/2007
16Cisplatin (Platino)FDA LinkGeneric
10/2021 - 08/2005
16Panitumumab (Vectibix)FDA Link
01/2020 - 01/2007
13pembrolizumabIBA
01/2022 - 03/2019
10RamucirumabIBA
10/2021 - 10/2014
10trifluridine tipiracil drug combinationIBA
01/2021 - 05/2015
10Biological ProductsIBA
01/2020 - 07/2006
10EverolimusFDA Link
01/2018 - 01/2010
9Paclitaxel (Taxol)FDA LinkGeneric
10/2022 - 10/2014
9Docetaxel (Taxotere)FDA Link
10/2022 - 01/2004
9afliberceptIBA
01/2020 - 10/2012
9regorafenibIBA
01/2019 - 01/2013
7DNA (Deoxyribonucleic Acid)IBA
08/2015 - 04/2008
6Peptide Receptors (Peptide Receptor)IBA
01/2022 - 01/2013
6Radioisotopes (Radionuclides)IBA
01/2022 - 01/2013
6Octreotide (Sandostatin)FDA LinkGeneric
12/2021 - 04/2010
6PlatinumIBA
10/2021 - 04/2012
6Trastuzumab (Herceptin)FDA Link
01/2021 - 08/2010
6Angiogenesis InhibitorsIBA
01/2019 - 01/2011
6XELOXIBA
11/2015 - 06/2004
5LigandsIBA
01/2022 - 10/2009
5thiamine triphosphorate (TTP)IBA
01/2022 - 06/2004
5Somatostatin Receptors (Somatostatin Receptor)IBA
12/2021 - 12/2017
5Sodium Glutamate (Accent)IBA
11/2021 - 07/2013
5ParaffinIBA
04/2014 - 04/2007
5Tyrosine Kinase InhibitorsIBA
10/2012 - 08/2005
4NivolumabIBA
10/2022 - 10/2018
4Proteins (Proteins, Gene)FDA Link
01/2022 - 08/2010
4Somatostatin (Somatotropin Release-Inhibiting Factor)IBA
10/2020 - 01/2015
4130-nm albumin-bound paclitaxelIBA
01/2020 - 10/2013
4Sorafenib (BAY 43-9006)FDA Link
01/2020 - 02/2013
4Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA
01/2019 - 03/2011
4Erlotinib Hydrochloride (CP 358,774)FDA Link
07/2012 - 08/2005
4AntibodiesIBA
12/2010 - 05/2007
3napabucasinIBA
07/2022 - 04/2019
3lutetium Lu 177 dotatateIBA
12/2021 - 12/2017
3binimetinibIBA
01/2021 - 10/2019
3Cell-Free Nucleic AcidsIBA
01/2021 - 08/2015
3encorafenibIBA
01/2021 - 10/2019
3RNA (Ribonucleic Acid)IBA
03/2020 - 01/2019
3AcriflavineIBA
01/2020 - 02/2017
3trametinibIBA
01/2020 - 02/2015
3Mitogen-Activated Protein Kinase Kinases (MEKs)IBA
01/2020 - 01/2018
3taxaneIBA
01/2019 - 04/2012
3velourIBA
01/2018 - 01/2014
3Codon (Codons)IBA
03/2015 - 10/2010

Therapy/Procedure

100Therapeutics
12/2022 - 04/2002
87Drug Therapy (Chemotherapy)
10/2022 - 01/2002
13Adjuvant Chemotherapy
11/2022 - 08/2004
8Radiotherapy
08/2021 - 12/2004
7Chemoradiotherapy
01/2020 - 01/2002
6Neoadjuvant Therapy
01/2021 - 03/2004
4Microspheres (Microsphere)
08/2020 - 08/2010
3Colectomy
04/2022 - 09/2011
3Radiofrequency Ablation
10/2017 - 02/2014
3Combination Drug Therapy (Combination Chemotherapy)
01/2016 - 08/2005